Maternal Infection Outcomes: Multicomponent Intervention
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- The SELECT trial specifically enrolled adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death – in individuals wiht obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk.Importantly,the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did not appear to offset this cardiovascular risk.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| cardiovascular Death | 1.5% | 1.2% |
| Nonfatal Stroke | 2.6% | 2.0% |
| Nonfatal Myocardial Infarction (Heart Attack) | 3.7% | 2.8% |
| MACE (Major Adverse Cardiovascular Event) | 6.5% | 4.9% |
Who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease. This is a crucial detail. The findings do *not* necessarily apply to individuals with obesity who do not have pre-existing heart conditions, or to those using semaglutide for type 2 diabetes management. Tho, the results raise concerns about the potential for increased risk in a significant and growing patient population.
It’s also important to note that the average age of participants was 61, and a substantial proportion had multiple cardiovascular risk factors, including hypertension and diabetes. This suggests the increased risk may be more pronounced in older individuals with complex health profiles.
Why This Matters: Beyond Weight Loss
Semaglutide, initially developed for type 2 diabetes, gained widespread popularity for its dramatic weight loss effects.The SELECT trial challenges the narrative that weight loss, in and of itself, guarantees improved cardiovascular health.It highlights the complex interplay between weight, metabolic factors, and underlying cardiovascular disease. Simply reducing body weight doesn’t automatically eliminate cardiovascular risk, and in some cases, may even introduce new risks.